High-dose Vitamin D to prevent bone loss in older prostate cancer patients on hormone therapy
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
This study is looking at whether taking high doses of vitamin D can help older men with prostate cancer who are on hormone therapy keep their bones strong and improve their strength and balance, making it less likely for them to have fractures or falls.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10983309 on NIH RePORTER |
What this research studies
This research investigates the effects of high-dose vitamin D supplementation on bone health in older prostate cancer patients undergoing androgen deprivation therapy (ADT). ADT can lead to significant bone mineral density loss and muscle mass reduction, increasing the risk of fractures and falls. The study aims to determine if administering high doses of vitamin D can mitigate these adverse effects, improve bone density, and enhance overall physical strength and balance. Participants will receive vitamin D supplementation and be monitored for changes in bone health and muscle function.
Who could benefit from this research
Good fit: Ideal candidates for this research are older prostate cancer patients aged 65 and above who are currently undergoing androgen deprivation therapy.
Not a fit: Patients who are not undergoing androgen deprivation therapy or are younger than 65 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help prevent bone loss and improve the quality of life for older prostate cancer patients receiving hormone therapy.
How similar studies have performed: Previous research has shown that high-dose vitamin D can effectively improve bone density in other populations, suggesting potential success for this approach in prostate cancer patients.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Peppone, Luke Joseph — University of Rochester
- Study coordinator: Peppone, Luke Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.